No services found
No Products found
Developing antibodies against cancer targets? Discover the world’s first Human Cancer Phage Display Library
Looking for a 100% reliable antibody for your research or diagnostic applications? Develop a custom mouse monoclonal antibody with the experts at ProteoGenix and benefit from a performance guarantee—ensuring that your antibody works in your specific application and in your hands! With over 3,000 mouse monoclonal antibodies successfully developed for our clients and our own catalog, we offer unmatched expertise to deliver the exact antibody you need.
Our custom mouse monoclonal antibodies are developed following application-specific protocols to ensure optimal validation. However, beyond all the validation data we can provide, the most crucial proof is that the antibody performs directly in your application. That’s why we created the “Test it, buy it only if satisfied” guarantee.
Test it
Validate it
Buy it
ELISA / Competitive ELISA
Sandwich ELISA
Western Blot
Flow cytometry
Immunohistochemistry / Immunofluorescence
Immunoprecipitation
Modification specific
Performance guarantee for your application
We ensure that your antibody works in your specific assay before purchase.
Validation across 9 applications
We guarantee that your antibody will work in one of the 9 application listed below.
Up to 50% faster timelines
Our proprietary RocketAbs platform accelerates immunization, reducing project duration by up to 20 days.
3,000+ mouse monoclonal antibodies developed
Extensive experience with 1,500+ client projects and 1,800+ antibodies in our catalog.
Two generation methods available
Select the most suitable approach for your project needs.
“We needed two monoclonal antibodies for Western Blot, from antigen synthesis to hybridoma development and purified antibody delivery. ProteoGenix exceeded our expectations with efficient communication, timely delivery, and successful production of specific and functional antibodies. They remain our preferred partner for future antibody production.”
Dr. Simon Marlaire, Senior Researcher, T3 Pharmaceuticals AG
“I required an anti-peptide monoclonal antibody for Western Blot and Immunoprecipitation. Despite immunogenicity challenges, ProteoGenix proposed tailored strategies that led to the successful generation of three high-quality antibodies, providing additional options for my research. Throughout the project, ProteoGenix demonstrated a commitment to quality and customer satisfaction.”
Dr. David Pryce, Lecturer in Biomedical Sciences (Immunology), Bangor University, UK
N Yacov et al., MOSPD2 is a therapeutic target for the treatment of CNS inflammation. Clin Exp Imm 201, (2) 105-20 (2020). https://doi.org/10.1111/cei.13448 PC Maity et al., IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. PNAS 117, (8) 4320-27 (2020). https://doi.org/10.1073/pnas.1913810117 P Cunha et al., Expansion, isolation and first characterization of bovine Th17 lymphocytes. Nature Sci Rep 9, 16115 (2019). https://doi.org/10.1038/s41598-019-52562-2 M Marco et al., Two-year post-distraction cartilage-related structural improvement is accompanied by increased serum full length SIRT1. Arthritis Research & Therapy 26, 106 (2024). https://doi.org/10.1186/s13075-024-03342-5 L Kis et al., Proof of concept for monoclonal antibody therapy in a cellular model of acquired long QT syndrome type 3. Am J Physiol Heart Circ Physiol 326, H89-95 (2024). https://doi.org/10.1152/ajpheart.00628.2023
A client required monoclonal antibodies for Flow Cytometry (FC) to detect a specific human cell membrane protein in vitro and in mice. The target protein posed significant challenges in mammalian cell expression.
Download our case study to discover:
We offer a diverse range of antigen design and immunization strategies to ensure the best antibody for your needs. Our in-house antigen production capabilities include peptides, proteins, DNA, and small molecules (haptens). Customer-provided antigens are also accepted.
The required antigen quantity depends on the antigen type and package selected. For immunization, we typically require 2 mg of protein or 5 mg of peptide-KLH. Additional quantities may be necessary depending on the package and can be produced upon request.
While conventional immunization protocols take approximately 60 days, ProteoGenix’s proprietary TiterFast™ adjuvant shortens this period to 22–43 days.
Antigen design is crucial for antibody generation. Every project begins with a preliminary antigen design evaluation to align with your final application’s needs. Based on this analysis, we develop tailored immunization and screening protocols to maximize the likelihood of obtaining the most relevant monoclonal antibodies. To further ensure relevance, we provide parental clone supernatants during early development, allowing you to test them directly in your samples and conditions. This approach enhances the final antibody selection process.
Our hybridoma development and single B-cell screening services include a dual-layer guarantee to minimize risks and secure your investment:
You only pay the full price if your custom antibody meets your performance requirements in your target application.
For hybridoma-based projects, our standard deliverables include:
For single B-cell screening projects, our deliverables include:
In each case, deliverables can be fully customized in discussion with your project manager.
+1 786 648 6837
inquiry-mabs@proteogenix.fr
Contact us
Got a question or need a quote? Message us and we'll get back to you 48 hours or less.
Your cart is currently empty.